• 제목/요약/키워드: protein therapy

검색결과 984건 처리시간 0.025초

X 연관 부신백질이영양증의 분류, 진단 및 치료의 최신 지견 (X-linked adrenoleukodystrophy; Recent Advances in Classification, Diagnosis and Management)

  • 정을식;고아라;강훈철
    • 대한소아신경학회지
    • /
    • 제24권3호
    • /
    • pp.71-83
    • /
    • 2016
  • X-linked adrenoleukodystrophy (X-ALD) is caused by mutations in the ATP binding cassette subfamily D member 1 (ABCD1), a gene that encodes peroxisomal membrane located on ABC half-transporter named adrenoleukodystrophy protein (ALDP). X-ALD is characterized by a highly variable clinical spectrum, including progressive cerebral type, adrenomyeloneuropathy, and addison-only phenotype. No genotype/phenotype correlation has been established. Thus, unidentified modifier genes and other co-factors are speculated to modulate the phenotypic variation and disease severity. Recent advanced sequencing methods and reprogramming technologies not only offer an affordable and applicable approach to investigate the pathophysiological mechanisms of adrenoleukodystrophy, but also provide means to develop therapy. A causal therapy of X-ALD is lacking. Lorenzo's oil therapy is recommended for asymptomatic boys, but the longest study found that the oil was not beneficial at all to symptomatic X-ALD patients. Hematopoietic stem cell therapy has a relevant chance of success when performed during this early stage of cerebral type X-ALD. Recently, it has been insisted that lentiviral-mediated gene therapy of hematopoietic stem cells can provide clinical benefits in X-ALD. This review describes current knowledge on the clinical presentation, pathogenesis, diagnosis and management of X- ALD.

Tat-CIAPIN1 protein prevents against cytokine-induced cytotoxicity in pancreatic RINm5F β-cells

  • Yeo, Hyeon Ji;Shin, Min Jea;Kim, Dae Won;Kwon, Hyeok Yil;Eum, Won Sik;Choi, Soo Young
    • BMB Reports
    • /
    • 제54권9호
    • /
    • pp.458-463
    • /
    • 2021
  • Cytokines activate inflammatory signals and are major mediators in progressive β-cell damage, which leads to type 1 diabetes mellitus. We recently showed that the cell-permeable Tat-CIAPIN1 fusion protein inhibits neuronal cell death induced by oxidative stress. However, how the Tat-CIAPIN1 protein affects cytokine-induced β-cell damage has not been investigated yet. Thus, we assessed whether the Tat-CIAPIN1 protein can protect RINm5F β-cells against cytokine-induced cytotoxicity. In cytokine-exposed RINm5F β-cells, the transduced Tat-CIAPIN1 protein elevated cell survivals and reduced reactive oxygen species (ROS) and DNA fragmentation levels. The Tat-CIAPIN1 protein reduced mitogen-activated protein kinases (MAPKs) and NF-κB activation levels and elevated Bcl-2 protein, whereas Bax and cleaved Caspase-3 proteins were decreased by this fusion protein. Thus, the protection of RINm5F β-cells by the Tat-CIAPIN1 protein against cytokine-induced cytotoxicity can suggest that the Tat-CIAPIN1 protein might be used as a therapeutic inhibitor against RINm5F β-cell damage.

Enhanced Transduction of Cu,Zn-Superoxide Dismutase with HIV-1 Tat Protein Transduction Domains at Both Termini

  • Eum, Won Sik;Jang, Sang Ho;Kim, Dae Won;Choi, Hee Soon;Choi, Soo Hyun;Kim, So Young;An, Jae Jin;Lee, Sun Hwa;Han, Kyuhyung;Kang, Jung Hoon;Kang, Tae-Cheon;Won, Moo Ho;Cho, Yong Joon;Choi, Jin Hi;Kim, Tae Yoon;Park, Jinseu;Choi, Soo Young
    • Molecules and Cells
    • /
    • 제19권2호
    • /
    • pp.191-197
    • /
    • 2005
  • The human immunodeficiency virus type 1 (HIV-1) Tat protein transduction domain (PTD) is responsible for highly efficient protein transduction across plasma membranes. In a previous study, we showed that Tat-Cu,Zn-superoxide dismutase (Tat-SOD) can be directly transduced into mammalian cells across the lipid membrane barrier. In this study, we fused the human SOD gene with a Tat PTD transduction vector at its N- and/or C-terminus. The fusion proteins (Tat-SOD, SOD-Tat, Tat-SOD-Tat) were purified from Escherichia coli and their ability to enter cells in vitro and in vivo compared by Western blotting and immunohistochemistry. The transduction efficiencies and biological activities of the SOD fusion protein with the Tat PTD at either terminus were equivalent and lower than the fusion protein with the Tat PTD at both termini. The availability of a more efficient SOD fusion protein provides a powerful vehicle for therapy in human diseases related to this anti-oxidant enzyme and to reactive oxygen species.

Protein transduction of an antioxidant enzyme: subcellular localization of superoxide dismutase fusion protein in cells

  • Kim, Dae-Won;Kim, So-Young;Lee, Hwa;Lee, Yeum-Pyo;Lee, Min-Jung;Jeong, Min-Seop;Jang, Sang-Ho;Park, Jin-Seu;Lee, Kil-Soo;Kang, Tae-Cheon;Won, Moo-Ho;Cho, Sung-Woo;Kwon, Oh-Shin;Eum, Won-Sik;Choi, Soo-Young
    • BMB Reports
    • /
    • 제41권2호
    • /
    • pp.170-175
    • /
    • 2008
  • In protein therapy, it is important for exogenous protein to be delivered into the target subcellular localization. To transduce a therapeutic protein into its specific subcellular localization, we synthesized nuclear localization signal (NLS) and membrane translocation sequence signal (MTS) peptides and produced a genetic in-frame SOD fusion protein. The purified SOD fusion proteins were efficiently transduced into mammalian cells with enzymatic activities. Immunofluorescence and Western blot analysis revealed that the SOD fusion proteins successfully transduced into the nucleus and the cytosol in the cells. The viability of cells treated with paraquat was markedly increased by the transduced fusion proteins. Thus, our results suggest that these peptides should be useful for targeting the specific localization of therapeutic proteins in various human diseases.

레트 증후군의 이해 (Understanding of Rett Syndrome)

  • 노효련
    • 대한물리의학회지
    • /
    • 제2권1호
    • /
    • pp.85-91
    • /
    • 2007
  • Purpose : The purpose of this study is understanding of Rett Syndrome. Rett Syndrome is a common developmental - neurologic disorder that has been reported almost exclusively in female. Recently mutations in the gene encoding X-linked methyl-CpG binding protein 2 (MECP2) have been identified as the cause of Rett syndrome. Consistent with the diagnostic criteria, hand skills, verbal or non - verbal communication skills and common motor skills were lost during regression. Regression most commonly occurred between 12 and 18 months of age. Methods : This is a literature study with books, articles, web site for Rett syndrome international association. Results : There is a continuing need to further elucidate the pre- and post - regression features of Rett syndrome. Rett syndrome need to physical therapy, musical therapy, special education and medical interventions. Conclusion : There has not been therapeutic method to the root of Rett syndrome but our goal is relaxation of symptom and physical therapist's study of Rett syndrome.

  • PDF

흰쥐 슬관절 고정 후 초음파 적용이 관절연골내 HSP70의 발현에 미치는 영향 (The Effects of Ultrasound Irradiation on the Heat Shock Protein 70(HSP70) Expression in Rat Knee Articular Cartilage after Immobilization)

  • 남기원
    • The Journal of Korean Physical Therapy
    • /
    • 제17권3호
    • /
    • pp.369-376
    • /
    • 2005
  • The purpose of the study was for investigating the effect of therapeutic ultrasound irradiation on HSP70 expression in knee of degraded rat articular cartilage. Knee of ten Sprague-Dawley male rats were immobilized for 4 weeks and divided at random into the control and continuous ultrasound applicated group. The continuous ultrasound applicated group was irradiated with frequency 1MHz, intensity $1W/cm^2$ for 5 minutes. The control group was sham sonication. The immunoreactivity of HSP70 was increased in degraded articular cartilage after untrasound irradiation. These results suggest that therapeutic ultrasound can enhance HSP70 expression in degraded articular cartilage.

  • PDF

Cancer-targeted photothermal therapy using aptamer-conjugated gold nanoparticles

  • Hong, Eun Ji;Kim, Yoon-Seok;Choi, Dae Gun;Shim, Min Suk
    • Journal of Industrial and Engineering Chemistry
    • /
    • 제67권
    • /
    • pp.429-436
    • /
    • 2018
  • Targeted intracellular delivery of therapeutic agents is one of the great challenges for cancer treatment. Aptamers that bind to a variety of biological targets have emerged as new targeting moieties with high specificity for targeted cancer therapy. In this study, near-infrared (NIR) light-absorbing hollow gold nanocages (AuNCs) were synthesized and conjugated with AS1411 aptamer to achieve cancer-targeted photothermal therapy. AuNC functionalized with PEG and AS1411 (AS1411-PEG-AuNC) exhibited selective cellular uptake in breast cancer cells due to selective binding of AS1411 to nucleolin, a protein that is over-expressed in cancer cells over normal cells. As a result, AS1411-PEG-AuNC showed cancer-targeted photothermal activity. This study demonstrates that aptamer-conjugated AuNCs are effective tumor-targeting photothermal agents.

A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab

  • Lee, Sang-Kyu;Cho, Yong-Hee;Cha, Pu-Hyeon;Yoon, Jeong-Soo;Ro, Eun Ji;Jeong, Woo-Jeong;Park, Jieun;Kim, Hyuntae;Kim, Tae Il;Min, Do Sik;Han, Gyoonhee;Choi, Kang-Yell
    • Experimental and Molecular Medicine
    • /
    • 제50권11호
    • /
    • pp.12.1-12.12
    • /
    • 2018
  • Drugs targeting the epidermal growth factor receptor (EGFR), such as cetuximab and panitumumab, have been prescribed for metastatic colorectal cancer (CRC), but patients harboring KRAS mutations are insensitive to them and do not have an alternative drug to overcome the problem. The levels of ${\beta}$-catenin, EGFR, and RAS, especially mutant KRAS, are increased in CRC patient tissues due to mutations of adenomatous polyposis coli (APC), which occur in 90% of human CRCs. The increases in these proteins by APC loss synergistically promote tumorigenesis. Therefore, we tested KYA1797K, a recently identified small molecule that degrades both ${\beta}$-catenin and Ras via $GSK3{\beta}$ activation, and its capability to suppress the cetuximab resistance of KRAS-mutated CRC cells. KYA1797K suppressed the growth of tumor xenografts induced by CRC cells as well as tumor organoids derived from CRC patients having both APC and KRAS mutations. Lowering the levels of both ${\beta}$-catenin and RAS as well as EGFR via targeting the $Wnt/{\beta}$-catenin pathway is a therapeutic strategy for controlling CRC and other types of cancer with aberrantly activated the $Wnt/{\beta}$-catenin and EGFR-RAS pathways, including those with resistance to EGFR-targeting drugs attributed to KRAS mutations.

Small Molecules Targeting for ESX-Sur2 Proteins' Interaction

  • Kwon, Young-Joo
    • 한국응용약물학회:학술대회논문집
    • /
    • 한국응용약물학회 2008년도 Proceedings of the Convention
    • /
    • pp.77-86
    • /
    • 2008
  • It's been known that overexpression of the oncoprotein Her2 (eu/ErbB2), transmembrane receptor protein, occurs in human breast cancer. Her2-positive breast cancer patients who have Her2 overexpression show less therapeutic efficacy with enhanced metathesis and increased resistance to chemotherapy. So far, a humanized monoclonal antibody against Her2 protein called Herceptin is the only drug approved by Food and Drug Administration for treatment of Her2-overexpressing breast tumors. However, antibody therapy of Herceptin may not be ideal method for therapeutic intervention of Her2 protein expression. The therapeutic intervention of Her2 protein expression may be more efficiently achieved by inhibiting the expression of Her2 gene rather than by down-regulating the Her2 protein already overexpressed. Here, we found that the interaction of two proteins of ESX (an epithelial-restricted transcription factor) and DRIP130/CRSP130/Sur2 (a Ras-linked subunit of human mediator complexes) mediates the expression of Her2 gene. The association of ESX with Sur2 is mediated by a small hydrophobic face of 8-amino acid helix in ESX, suggesting that the ESX-Sur2 interaction can be a new novel target for Her2-positive cancer. The process to develop potent ESX-Sur2 interaction inhibitors targeting for Her2-positive cancer therapeutics will be discussed.

  • PDF

Power and Promise of Ubiquitin Carboxyl-terminal Hydrolase 37 as a Target of Cancer Therapy

  • Chen, Yan-Jie;Ma, Yu-Shui;Fang, Ying;Wang, Yi;Fu, Da;Shen, Xi-Zhong
    • Asian Pacific Journal of Cancer Prevention
    • /
    • 제14권4호
    • /
    • pp.2173-2179
    • /
    • 2013
  • Ubiquitin carboxyl-terminal hydrolase 37 (UCH37, also called UCHL5), a member of the deubiquitinating enzymes, can suppress protein degradation through disassembling polyubiquitin from the distal subunit of the chain. It has been proved that UCH37 can be activated by proteasome ubiqutin chain receptor Rpn13 and incorporation into the 19S complex. UCH37, which has been reported to assist in the mental development of mice, may play an important role in oncogenesis, tumor invasion and migration. Further studies will allow a better understanding of roles in cell physiology and pathology, embryonic development and tumor formation, hopefully providing support for the idea that UCH37 may constitute a new interesting target for the development of anticancer drugs.